Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good day everyone and welcome to today’s Avadel Pharmaceuticals ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and EuropeCompleted ZYNQUISTA™ FDA ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Cantor Fitzgerald has recently initiated ARS Pharmaceuticals Inc (SPRY) stock to Overweight rating, as announced on August 20, 2024, according to Finviz. Earlier, on August 13, 2024, Raymond James had ...

The USD Index needs to break and hold above 105.70 for a decisive move toward 106.13 and 106.30, UOB Global Economics & Markets Research said. Descending trendline resistance connecting the highs of ...

It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

The 30 treatment centers Autolus is ready to authorize in the upcoming weeks should cover around 60% of the target population. Over the next 12 months, that number will swell to 60 centers that can ...

On Friday, Recursion Pharmaceuticals Inc (RXRX) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.17 or 2.45% from the prior close of $6.93. The stock opened ...

Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...

Today, pharma companies are carefully balancing the effectiveness and the return on investment of traditional sales visits ...

Prabhudas Lilladher is bullish on Apollo Hospitals Enterprise has recommended buy rating on the stock with a target price of ...